To be the best,
we work with the best

 

SkylineDx is on a mission. To revolutionize the future of personalized medicine today. In order to make important steps in the conservative landscape we collaborate with academic institutes, hospitals and patient associations that are ahead in their field. The rebels that help us change the landscape.

 

We are inspired by the many collaborations that prove we are not in the battle alone.

 

#amazingthingshappen


Erasmus Medical Center, Rotterdam, The Netherlands

Erasmus Medical Center has granted us a worldwide exclusive license on the commercial use of their patent families in the area of diagnostics and prognosis of leukemia, multiple myeloma and acute myeloid leukemia signature gene expression. Together, we performed collaborative research on patient data sets and sample sets, for further expansion of MMprofiler™ and for new product development.

University Medical Center Utrecht, The Netherlands

The University Medical Center Utrecht (UMCU) is our clinical partner for the current study for the APprofiler. In this partnership a clinical study is ongoing in which a minimum of 900 non-acute chest pain patients participate. We believe that the early study results have shown that our sample work-up process is repeatable and our quality control requirements are sufficient to generate high value data.


Multiple Myeloma Research Foundation (MMRF), USA

Together with the MMRF, we are working on collaborative research on all genomic aspects of multiple myeloma focused on the disease prognosis.

 

Ribeirão Preto Medical School, University of Sao Paolo, Brazil

With the Ribeirão Preto Medical School at the University of Sao Paolo we have set up an extensive study on acute myeloid leukemia (AML) patients from South America, using our AMLprofiler. The objective of the study is to improve diagnosis and determine the feasibility of autologous stem cell transplantation as consolidation treatment for patients with low- or intermediate risk of AML.